Mulpleta (lusutrombopag) is approved in Japan to treat thrombocytopenia associated with chronic liver disease- Shionogi
Shionogi has announced marketing approval in Japan for Mulpleta (lusutrombopag) tablets 3 mg for the improvement of thrombocytopenia-associated chronic liver disease patients undergoing an elective invasive procedure. Lusutrombopag is a small molecule thrombopoietin receptor agonist discovered by Shionogi which induces proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes consequently increasing platelet counts.
Comment: Mulpleta is expected to become an alternative to platelet transfusion for patients with chronic liver disease in order to increase platelet levels prior to elective invasive procedures.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.